SEN-OA Targeting senescent cells in OA

Objectives of the Project

The main risk factor for Osteoarthritis (OA) is ageing. An emerging concept for age-related diseases is that senescent cells accumulate with time and release SASP (senescence-associated secretory profile) products, which alter tissue functions. Accumulation of senescent cells during lifespan is believed to contribute to progressive tissue loss of functions. Specific elimination of these cells could prevent some age-associated diseases.

Within the SEN-OA consortium, we propose a multifaceted approach combining innovative biomedical senescence models, ageing animal studies, human sample analyses and screening for senescence-targeting compounds for clinical application to (i) decipher the role of ageing-associated senescence mechanisms in the appearance of OA and (ii) develop innovative treatments for OA patients

Facts and Figures

Project lead
PhD D Noël
INSERM UMR 1183
FOREUM research grant: € 600.000
2018, Duration 3 years

Meet the team

PhD D Noël
INSERM UMR 1183
MD, PhD C Jorgensen
INSERM UMR 1183, CHU Montpellier
PhD X Houard
INSERM UMRS 938 - Université Pierre et Marie Curie
Pharm.D, Ph.D C Caramés Perez
INIBIC
Mr L Comole
Arthritis Courtin Fondation
PhD J Guicheux
INSERM UMR 1229, Université de Nantes
PhD C Vinatier
INSERM, UMR 1229, RMeS - Université de Nantes
MD, PhD F Rannou
Centre Universitaire des Saints-Pères
PhD P van der Kraan
Radboud UMC

Patient Voice

Patients will be involved through the ”Fondation Arthritis Courtin”, as a full patient research partner. This Foundation is supported by patients suffering from rheumatism and musculoskeletal diseases and acts through many types of action, such as regular one-day meetings to provide dedicated information to patients or regular public publications for dissemination of science. ”Fondation Arthritis Courtin” will help in valorization and dissemination to a broad audience through meetings and various media supports (Internet, press release and patient-focused publications, etc. We propose to set a Scientific Advisory Board, which will be constituted by two scientific experts and one patient expert, who will follow the progress of the project during a one-day meeting each year.